A detailed history of Cetera Investment Advisers transactions in Vaxcyte, Inc. stock. As of the latest transaction made, Cetera Investment Advisers holds 5,127 shares of PCVX stock, worth $440,460. This represents 0.0% of its overall portfolio holdings.

Number of Shares
5,127
Previous 4,728 8.44%
Holding current value
$440,460
Previous $357,000 63.87%
% of portfolio
0.0%
Previous 0.0%

Shares

3 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 13, 2024

BUY
$70.52 - $117.12 $28,137 - $46,730
399 Added 8.44%
5,127 $585,000
Q2 2024

Aug 22, 2024

BUY
$60.06 - $78.77 $14,894 - $19,534
248 Added 5.54%
4,728 $357,000
Q1 2024

May 24, 2024

BUY
$59.79 - $81.05 $267,859 - $363,104
4,480 New
4,480 $306,000

Others Institutions Holding PCVX

About Vaxcyte, Inc.


  • Ticker PCVX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 59,315,100
  • Market Cap $5.1B
  • Description
  • Vaxcyte, Inc., a clinical-stage biotechnology vaccine company, develops novel protein vaccines to prevent or treat bacterial infectious diseases. Its lead vaccine candidate is VAX-24, a 24-valent investigational pneumococcal conjugate vaccine that is in Phase 1/2 clinical trials to treat invasive pneumococcal disease and pneumonia. The company a...
More about PCVX
Track This Portfolio

Track Cetera Investment Advisers Portfolio

Follow Cetera Investment Advisers and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Cetera Investment Advisers, based on Form 13F filings with the SEC.

News

Stay updated on Cetera Investment Advisers with notifications on news.